GI Innovation & J&J are teaming up for a Phase 1b trial combining immune-boosting GI-102 with J&J’s bispecific T-cell engager pasritamig.
Excited or skeptical? Drop your thoughts!
aktiego.com/sectors/biot...
#ProstateCancer #Immunotherapy #CancerResearch #GIInnovation #Oncology
Excited or skeptical? Drop your thoughts!
aktiego.com/sectors/biot...
#ProstateCancer #Immunotherapy #CancerResearch #GIInnovation #Oncology
GI Innovation and J&J Team Up to Tackle Advanced Prostate Cancer - AktieGo
GI Innovation and Johnson & Johnson are testing a combination immunotherapy in metastatic castration-resistant prostate cancer. Here's what the trial means.
aktiego.com
March 24, 2026 at 6:49 AM
GI Innovation & J&J are teaming up for a Phase 1b trial combining immune-boosting GI-102 with J&J’s bispecific T-cell engager pasritamig.
Excited or skeptical? Drop your thoughts!
aktiego.com/sectors/biot...
#ProstateCancer #Immunotherapy #CancerResearch #GIInnovation #Oncology
Excited or skeptical? Drop your thoughts!
aktiego.com/sectors/biot...
#ProstateCancer #Immunotherapy #CancerResearch #GIInnovation #Oncology